The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
Michael Vavuranakis, Steven R. Jones, Efthymios Ziogos, Michael J. Blaha, Marlene S. Williams, Palmer Foran, Thomas H. Schindler, Shenghan Lai, Steven P. Schulman, Gary Gerstenblith, Thorsten M. Leucker
Topics & Concepts
MedicineEvolocumabPCSK9Myocardial infarctionPlaceboInternal medicineLipoprotein(a)CardiologyLipoproteinSubtilisinKexinGastroenterologyEndocrinologyCholesterolLDL receptorEnzymeChemistryAlternative medicineBiochemistryPathologyApolipoprotein A1Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research